Abstract
Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Keywords: Obesity, eating disorders, reward deficit, addiction
Current Pharmaceutical Design
Title: Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction
Volume: 17 Issue: 5
Author(s): Luis F Alguacil, Elisabet Salas and Carmen Gonzalez-Martin
Affiliation:
Keywords: Obesity, eating disorders, reward deficit, addiction
Abstract: Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Export Options
About this article
Cite this article as:
F Alguacil Luis, Salas Elisabet and Gonzalez-Martin Carmen, Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164158
DOI https://dx.doi.org/10.2174/138161211795164158 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Nesfatin-1; Implication in Stress and Stress-associated Anxiety and Depression
Current Pharmaceutical Design Sleep, Depression and Insomnia – A Vicious Circle?
Current Psychiatry Reviews Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets Mossy Fiber Sprouting as a Potential Therapeutic Target for Epilepsy
Current Neurovascular Research The Orexinergic (Hypocretin) System and Nociception: An Update to Supraspinal Mechanisms
Current Medicinal Chemistry Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine Alzheimers Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
Current Drug Targets - CNS & Neurological Disorders Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology Intracranial Collateral Flow Estimated by Color Velocity Imaging Quantification Ultrasound: A Protector of Recurrent Stroke in Patient with Carotid Stenosis?
Current Neurovascular Research Ameliorative Effects of GW1929, a Nonthiazolidinedione PPARγ Agonist,on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury
Current Neurovascular Research Anti-Inflammatory Effects of Physical Activity in Relationship to Improved Cognitive Status in Humans and Mouse Models of Alzheimers Disease
Current Alzheimer Research Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine The Alcohol Hangover Research Group Consensus Statement on Best Practice in Alcohol Hangover Research
Current Drug Abuse Reviews Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy A Systematic Review of Lifestyle Modification and Glucose Intolerance in the Prevention of Type 2 Diabetes
Current Diabetes Reviews Phase-Change Contrast Agents for Imaging and Therapy
Current Pharmaceutical Design G Protein-Coupled Receptor Signaling Complexity in Neuronal Tissue:Implications for Novel Therapeutics
Current Alzheimer Research